News

Categories

December 14, 2022

Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

December 9, 2022

New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS

November 21, 2022

Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)

November 10, 2022

Zymeworks Presents Preclinical Data on TLR7 ISACs technology at the Society for Immunotherapy of Cancer (SITC) Conference

November 1, 2022

November is Stomach Cancer Awareness Month

October 20, 2022

Zymeworks Early R&D Day Highlights Progress In Development Of Novel Pipeline Assets And Applications Of Proprietary Next-Generation Technology Platforms

October 19, 2022

Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody

October 5, 2022

Zymeworks to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) Conference

October 4, 2022

Zymeworks Announces Participation In Upcoming Investor Conferences And Early Research & Development Day

September 12, 2022

Zymeworks Reports Preliminary Phase 1 Trial Results For Zanidatamab Zovodotin (ZW49) At European Society For Medical Oncology Annual Congress

September 4, 2022

Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers

August 4, 2022

Zymeworks Provides Corporate Update And Reports Second Quarter 2022 Financial Results